Guggenheim Reiterates Buy Rating on Adaptive Biotechnologies Corporation (ADPT)

Market Context

Adaptive Biotechnologies Corporation operates in the Healthcare sector. The stock currently trades at $24.18 with a market capitalization of $2.4B. The stock has gained 132.7% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Adaptive Biotechnologies Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Adaptive Biotechnologies Corporation

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 30, 2026	TD Cowen	Buy	N/A
Jul 30, 2026	Morgan Stanley	Equal-Weight	N/A
Jul 30, 2026	Guggenheim	Buy	N/A
Jul 30, 2026	BTIG	Buy	N/A
Jul 09, 2026	Morgan Stanley	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View ADPT Stock Page